欧美成在线 I 色吧伊人 I 亚洲综合国产成人无码 I 欧美最新在线 I 国内少妇偷人精品视频 I 人人插人人 I 综合一区在线 I 欧美一二三级 I 欧美视频一区在线观看 I 成年无码av片在线狼人 I av片一区 I 日本老熟妇乱 I 人人看人人澡 I 日韩av免费无码一区二区三区 I 善良的妈妈在线播放 I 唯美欧美亚洲 I 免费看的黄色网址 I 老头吃奶性行交视频 I 国产激情三区 I 亚洲成av人片无码迅雷下载 I 欧美大屁股流白浆xxxx I 四虎官网 I 日本高清www I 国产精品久久嫩一区二区免费 I 亚洲乱亚洲乱妇在线观看 I 波多野结衣黄 I 欧美丰满熟妇xxxx性多毛 I 在线免费播放毛片 I 中国精品偷拍区偷拍无码 I 久久人人av I 亚洲精品色婷婷在线影院 I 粉嫩av中文字幕 I 一区二区三区四区五区视频在线观看 I 国产丝袜在线播放 I 顶级嫩模被啪啪得娇喘呻吟

一.產(chǎn)品名稱：

通用名稱：甲狀旁腺激素1-34 ELISA試劑盒

英文名稱：PTH 1-34 ELISA Kit

二.PTH 1-34 ELISA Kit介紹：

Teriparatide (rhPTH 1-34) is a recombinant human parathyroid hormone derivative consisting of the first 34 amino acids of the hormone. Teriparatide was approved as a drug by the FDA in 2002 and is sold by Eli Lilly & Co. under the brand name Forteo. Teriparatide is indicated for use in patients with osteoporosis. It is currently administered by injection and has an anabolic effect on bone, binding to the PTH/PTHrp Type 1 receptor with the same affinity as the intact molecule, PTH (1-84). This receptor activation results in a series of events leading to the formation of new trabecular and cortical bone. Research is continuing at pharmaceutical and biotech companies to pursue similar drugs and alternate delivery pathways.
Immunogenicity for this drug, defined as the presence of antibodies to human PTH (1-34), was detected in 2.8% of women receiving teriparatide during the clinical trials of Forteo. The detection of these
circulating antibodies may be of clinical relevance for the proper assessment of patients.

如需了解更多產(chǎn)品資料，請北京科瑞美公司。